Hospital Universitari Vall d'Hebron Research Institute
vhir.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
267
Active
51
Phase 3
17
Total enrollment
145,544
Pipeline matrix
Showing 14 of 14 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Continue low dose calcineurin inhibitor | — | — | — | — | — | 1 | |
| Calcineurin inhibitor withdrawal at 6 months | — | — | — | — | — | 1 | |
| Indocyanine green | — | — | — | — | — | 1 | |
| Early Discontinuation of Antibiotics | — | — | — | — | — | 1 | |
| Standard Antibiotic Continuation Strategy | — | — | — | — | — | 1 | |
| 3D printed chewable formulation of hydrocortisone | — | — | — | — | — | 1 | |
| Oral suspension of hydrocortisone | — | — | — | — | — | 1 | |
| Discontinuation of Acetylsalicilic acid 150 mg/day at 24-28 weeks of gestation | — | — | — | — | — | 1 | |
| Autologous Hematopoietic Stem Cell Transplantation | — | — | — | — | — | 1 | |
| Analysis of genetic modifiers | — | — | — | — | — | 1 | |
| Esketamine Treatment as Usual | — | — | — | — | — | 1 | |
| Sumatriptan | — | — | — | — | — | 1 | |
| CONVENTIONAL ACUTE STROKE MANAGEMENT | — | — | — | — | — | 1 | |
| CGRP antibody or gepant | — | — | — | — | — | 1 |
Next readouts
- 2024-12
- 2025-05-25
- 2025-09
- 2025-12
- 2026-01
- 2026-03-19
- 2026-12-15
- 2027-05
- 2028-01-31
- 2028-05
Top conditions
- Healthy17
- Fibromyalgia8
- Dyspepsia7
- Stroke5
- Acute Respiratory Failure5
- Irritable Bowel Syndrome5
- Cirrhosis4
- Hepatic Encephalopathy4
Frequently asked questions about Hospital Universitari Vall d'Hebron Research Institute
- How many clinical trials does Hospital Universitari Vall d'Hebron Research Institute have on ClinicalTrials.gov?
- Hospital Universitari Vall d'Hebron Research Institute is listed as the lead sponsor on 267 clinical trials in ClinicalTrials.gov, 51 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hospital Universitari Vall d'Hebron Research Institute's trials are in Phase 3?
- 17 of Hospital Universitari Vall d'Hebron Research Institute's trials are in Phase 3, spread across 14 active drug programs.
- What therapeutic areas does Hospital Universitari Vall d'Hebron Research Institute focus on?
- Hospital Universitari Vall d'Hebron Research Institute's most-studied conditions on ClinicalTrials.gov are Healthy, Fibromyalgia, Dyspepsia, Stroke, Acute Respiratory Failure.
- When are Hospital Universitari Vall d'Hebron Research Institute's next clinical trial readouts?
- Hospital Universitari Vall d'Hebron Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I”, expected around 2024-12.